What We're Reading
Industry reads hand-picked by our editors
Apr 26, 2024
-
Financial Times
Bristol Myers Squibb drafts contingency plans for US restrictions on Chinese pharma
-
Reuters
Bayer investor Deka takes a stand against CEO in annual vote
-
LifeSciVC
The Biotech Startup Contraction Continues... And That’s A Good Thing
-
MedTech Dive
Freenome to cut more than 100 employees in restructuring
Apr 25, 2024
-
Reuters
GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology
-
CNBC
Merck beats earnings expectations, raises outlook on strong Keytruda and vaccine sales
-
The Wall Street Journal
McKinsey Under Criminal Investigation Over Opioid-Related Consulting
-
The Economist
Many mental health conditions have bodily triggers
Apr 24, 2024
-
Financial Times
GSK readies for pivotal ruling in Zantac cases
-
ApexOnco
Roche trims its pipeline again
-
Reuters
About 3.6 mln Medicare beneficiaries could be eligible for Wegovy coverage, study shows
-
Stat
FDA approves Day One’s drug for common childhood brain tumor
-
None
Biogen sees ‘encouraging’ trends for postpartum depression drug
Apr 23, 2024
Apr 22, 2024
Apr 19, 2024
-
The Atlantic
The Bone-Marrow-Transplant Revolution
-
Bloomberg
Seasonal Allergies Are Getting Worse Because of Global Warming
-
Reuters
China’s drugmakers can’t sell mRNA shots but haven’t quit yet
-
The Wall Street Journal
Influencers Love Ozempic—but They Aren’t Telling You About the Risks
Apr 18, 2024
-
The Washington Post
Cancer could soon be detected by blood tests, even before symptoms
-
CNN
‘Kids need to breathe just like adults do:’ $35 price caps don’t apply to asthma meds young children need, doctors say
-
BioCentury
Drive-by analysis of accelerated approval is intellectual malpractice
-
Time
Stuart Orkin is on the 2024 TIME100 List